- Home
- IOBT vs QNRX Comparison
IOBT vs QNRX Comparison
Compare IOBT & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOBT | QNRX |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 11.6M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IOBT | QNRX |
|---|---|---|
| Price | $0.04 | $4.28 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | ★ 186.6M | 26.5K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $4.55 |
| 52 Week High | $2.79 | $41.80 |
Technical Indicators
Market Signals| Indicator | IOBT | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 25.94 | 28.20 |
| Support Level | N/A | N/A |
| Resistance Level | $0.22 | $6.84 |
| Average True Range (ATR) | 0.02 | 0.46 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 15.92 | 14.39 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.